Business Description
Nykode Therapeutics AS
ISIN : NO0010714785
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 28.71 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 8.12 | |||||
Beneish M-Score | 175.05 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -58.5 | |||||
3-Year Book Growth Rate | 0.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | -27.86 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.61 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 98.45 | |||||
9-Day RSI | 88.7 | |||||
14-Day RSI | 76.72 | |||||
6-1 Month Momentum % | -5.06 | |||||
12-1 Month Momentum % | -36.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.43 | |||||
Quick Ratio | 8.43 | |||||
Cash Ratio | 8.17 | |||||
Days Sales Outstanding | 6.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | -0.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -553.47 | |||||
Net Margin % | -373.34 | |||||
FCF Margin % | -865.69 | |||||
ROE % | -26.65 | |||||
ROA % | -20.58 | |||||
ROIC % | -116.74 | |||||
ROC (Joel Greenblatt) % | -466.7 | |||||
ROCE % | -28.89 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 39.61 | |||||
PB Ratio | 2.77 | |||||
Price-to-Tangible-Book | 2.78 | |||||
EV-to-EBIT | -6.04 | |||||
EV-to-EBITDA | -6.33 | |||||
EV-to-Forward-EBITDA | -4.76 | |||||
EV-to-Revenue | 27.68 | |||||
EV-to-Forward-Revenue | 14.82 | |||||
EV-to-FCF | -3.22 | |||||
Price-to-Net-Current-Asset-Value | 3.75 | |||||
Price-to-Net-Cash | 3.85 | |||||
Earnings Yield (Greenblatt) % | -16.56 | |||||
FCF Yield % | -20.9 |